Healthcare
Protara Therapeutics, Inc.(TARA)
Live Price
Offline$3.98
-2.21% today
1Y Change
+41.32%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $210.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +38.2%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Protara Therapeutics, Inc. (TARA) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $3.98 and up 41.3% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +38.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +38.2%, free cash flow -57.4% with operating margin 0.0% and ROIC -32.3%. Stock Foundry combines TARA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +38.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.8% | -6.2% | -26.4% |
2026 Mar 10, 2026 | -15.6% | -1.9% | -4.6% | -8.6% |
2025 Nov 10, 2025 | +20.5% | +18.3% | +23.0% | +26.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TARA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TARA Max Drawdown
-51.72%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TARA and SPY.
Company Overview
Protara Therapeutics, Inc.
NASDAQ Global Market
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
- Leadership
- Jesse Shefferman
- IPO Date
- Oct 22, 2014
- Employees
- 28
- Street Address
- 345 Park Avenue South
- Mailing
- New York City, NY, 10010
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 646 844 0337
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.2
Growth
- Revenue
- 0.0%
- EPS
- +38.2%
- Free Cash Flow
- -57.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -36.4%
- ROIC
- -32.3%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 14.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.